+53.9%
F vs GSK
+48.0%
+5.9%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.5% | -1.9% | +3.4% | +2.0% |
| 7D | +5.3% | -1.8% | +7.2% | +5.8% |
| 30D | +4.6% | -2.2% | +6.8% | +5.1% |
| 3M | -3.7% | -1.8% | -1.8% | -3.4% |
| 6M | +16.8% | -10.6% | +27.4% | +20.0% |
| YTD | +15.3% | +4.4% | +10.9% | +13.8% |
| 1Y | +31.0% | +30.4% | +0.6% | +21.2% |
| 3Y | +45.4% | +60.1% | -14.6% | +22.0% |
| All | +53.9% | +48.0% | +5.9% | +20.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling